• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Lundbeck Canada donates $2.7 million towards depression study

Lundbeck Canada donates $2.7 million towards depression study

August 30, 2011
CenterWatch Staff

The Canadian subsidiary of neurological disease specialist Lundbeck has donated $2.7 million towards a nationwide study aimed at identifying biomarkers of major depression and bipolar disorder, according to PharmaTimes.

Lundbeck Canada’s donation will fund the Canadian Depression Biomarker Network, a research initiative involving six academic centers across Canada and led by the Toronto-based University Health Network.

The six centers are the University Health Network (comprising Toronto General and Toronto Western hospitals, Princess Margaret Hospitals and the Toronto Rehabilitation Institute), the Ontario Cancer Biomarker Network, McMaster University, Queen’s University, the University of British Columbia and the University of Calgary.

Future treatment of mood disorders lies in personalized medicine, which entails identifying biomarkers and developing targeted therapies, said Lundbeck Canada and its partners. This in turn calls for large-scale studies to define accurately sub-populations.

The biomarker approach combines clinical data (including measures of anxiety, cognition, function/quality of life, life events, personality and symptom severity) with molecular data to provide measures of gene and protein function in the body as well as brain scans that characterize the function of important mood-regulating brain circuits, the partners noted.

The Canadian Depression Biomarker Network will conduct a large-scale, nationwide research project in which detailed clinical, neuro-imaging, genetic and molecular data will be collected from people with depression during a standardized, two-stage course of treatment.

The research team will then identify individuals whose symptoms remitted and those whose symptoms did not. Informatics and mathematical modeling techniques will be used to profile individual patients, make personalized predictions about treatment responses, develop appropriate treatment algorithms and identify new therapeutic targets.   

Around one in eight people in Canada will develop depression during their lifetime, with the total cost to the Canadian economy estimated at $51 billion per year.

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing